Qatar launches first brain scanning service to catch Alzheimer’s early

Qatar's largest healthcare provider has started offering a brain imaging service that can detect Alzheimer's disease in its earliest stages. Hamad Medical Corporation (HMC) launched the amyloid brain PET-CT service in late April, making Qatar the first country in the region to offer this type of scanning.

The technology can spot beta-amyloid protein deposits in the brain years before patients show obvious symptoms of dementia. This early detection could help doctors start treatment sooner and give families more time to plan for the disease's progression.

How does it work?

The amyloid PET-CT scan works by injecting patients with a radioactive tracer that binds to beta-amyloid proteins in the brain. These proteins clump together to form plaques that are a hallmark of Alzheimer's disease.

The process involves several key steps:

• Patients receive an injection of the radioactive tracer
• The tracer travels to the brain and attaches to amyloid plaques
• A PET-CT scanner captures detailed images showing where the plaques have formed
• Doctors can then see the extent and location of amyloid buildup

The scan is non-invasive and takes about 90 minutes from start to finish. Results can help doctors distinguish Alzheimer's from other types of dementia that may have similar symptoms but different underlying causes.

Why does it matter?

Early detection of Alzheimer's could change how doctors approach treatment. While there's no cure for the disease, catching it early gives patients and families crucial time to make decisions about care, finances, and living arrangements.

The imaging also helps doctors make more accurate diagnoses in complex cases. About 40% of dementia cases are initially misdiagnosed, according to medical research. Having a clearer picture of what's happening in the brain can prevent patients from receiving the wrong treatments.

For Qatar specifically, this technology addresses a growing healthcare challenge. The country's population is aging, and dementia cases are expected to rise significantly over the next two decades.

The context

Qatar has been investing heavily in advanced medical technology as part of its National Vision 2030 healthcare goals. The amyloid PET-CT service represents the latest addition to HMC's nuclear medicine capabilities.

The service launched through a partnership between HMC's Clinical Imaging Department and the Geriatric Memory Clinic at Rumailah Hospital. The first patients were scanned on April 23, with the service now available to eligible patients referred by their doctors.

Globally, amyloid PET imaging has gained approval from major health regulators including the FDA and European Medicines Agency. The technology is becoming more widely available in developed countries, though Qatar appears to be among the first in the Middle East to offer the service.